(19)
(11) EP 1 220 864 A1

(12)

(43) Date of publication:
10.07.2002 Bulletin 2002/28

(21) Application number: 00963586.3

(22) Date of filing: 18.09.2000
(51) International Patent Classification (IPC)7C07H 21/04, C07K 1/00, C07K 14/00, C12N 15/00, C12N 15/12, C12N 15/13, C12P 21/00
(86) International application number:
PCT/US0025/560
(87) International publication number:
WO 0119/846 (22.03.2001 Gazette 2001/12)
(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: 17.09.1999 US 398610

(71) Applicants:
  • THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Rockville, MD 20852-3804 (US)
  • Astrazeneca Limited
    London W1Y 6LN (GB)
  • The United States of America,represented by The Secretary,Dept. of Health and Human Services, the Natl. Institutes of Health
    Rockville, MD 20852-3804 (US)

(72) Inventors:
  • EDGE, Michael, D.
    Macclesfield,Cheshire SK10 4TG (GB)
  • POLLOCK, Dan
    Medway, MA 02053 (US)
  • ECHELARD, Yann
    Jamaica Plain, MA 02130-3007 (US)
  • MEADE, Harry, M.
    Newton, MA 02158 (US)
  • RYBAK, Susanna, M.
    Frederick, MD 21702 (US)

(74) Representative: Ruffles, Graham Keith et al
MARKS & CLERK,57-60 Lincoln's Inn Fields
London WC2A 3LS
London WC2A 3LS (GB)

   


(54) TRANSGENICALLY PRODUCED FUSION PROTEINS